| Revenue Growth | Total sales $27.2M; True Niagen $23.3M (down 10%); Ingredients $3.8M. |
|---|---|
| Mgmt Confidence | High for 2027 expansion; 2026 characterized as a foundational investment year. |
| Demand Visibility | Sequential Q4 improvement expected; Watson's orders expected to return to normal. |
| Margin Trends | Gross margin 62.9% vs 64.5% prior year due to product mix. |
| Op. Leverage | S&M expense rose to 32% of sales from 25.8% prior year. |
| Pricing Power | Pricing remains a hurdle for ingredient customers due to NMN competition. |
| Vol vs Price | Growth driven by DTC volume; ingredient revenue impacted by order timing. |
| Segment Growth | DTC website grew 17% adjusted; distribution revenue lagged due to timing. |
| New Clients | Added Walmart.com, 300 GNC locations, Sam's Club, and Restore Hyper Wellness. |
| Capex & Debt | $69.5M cash, zero debt, $14.6M remaining on share repurchase authorization. |
| Regulatory | FDA lawsuit regarding NMN; pursuing IND-enabling studies for NB4168 drug candidate. |
| Commentary | Focusing on 'Better NAD' differentiation through scientific rigor and patent enforcement. |
| New Launches | Nano Cloud skincare, at-home injection kits, and upcoming 2027 salt form. |
Growth
Total sales fell 10% to $27.2M; DTC website grew 13% (17% adjusted).
Outlook
Targeting 2027 for commercialization of lower-cost salt forms and first-in-human pharmaceutical trials.
Risks
Management pivoted on G&A/litigation costs, citing 'certain periods' without providing specific future dollar targets.
The company's earnings call, NASDAQ: NAGE, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Niagen Bioscience, Inc.: key numbers
- Share price
- $2.01Close, Nov 16
- Market cap
- $159M
- Shares outstanding
- 79.2MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Niagen Bioscience, Inc.
All →Niagen Bioscience Q3 2026 Results: Net Loss of $1.17M
Niagen Bioscience reported a net loss of $1.2 million for the third quarter of 2026, a significant decline from a $4.6 million profit in the prior year, driven by a 20% decrease in net sales. However, for the nine-month period, the company remained profitable with a net income of $6.1 million, bolstered by a $4.8 million gain from the sale of an operating segment.
- Key figure
- Net loss $1.17M
Niagen Bioscience Financial Results
Niagen Bioscience reported Q3 2026 net sales of $27.2 million and a net loss of $1.2 million, while generating $2.6 million in operating cash flow. The company launched several new products including Niagen NanoCloud topical and an at-home injection kit, while expanding retail distribution through Walmart.com, GNC, and Sam's Club.
- Term
- Q3 2026
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform. We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”
Rob Fried, Chief Executive Officer